IL4 and cancer: These included interleukin 4, receptor of the NFKB ligand (RANKL-RANK) signaling pathway, and type II interferon signaling pathways, all of which are immune-related pathways RANKL-RANK in particular is dysregulated in many types of cancer, including oral SCC, and may be a therapeutic target43.